<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://tpx.sagepub.com">
<title>Toxicologic Pathology recent issues</title>
<link>http://tpx.sagepub.com</link>
<description>Toxicologic Pathology RSS feed -- recent issues</description>
<prism:publicationName>Toxicologic Pathology</prism:publicationName>
<prism:issn>0192-6233</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/6/705?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/708?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/714?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/733?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/741?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/754?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/761?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/770?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/776?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/790?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/799?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/805?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/814?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/6/819?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/6/826?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/5/569?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/5/570?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/5/572?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/5/594?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/5/599?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/5/606?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/5/617?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/5/629?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/5/644?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/5/661?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/5/667?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/5/672?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/5/677?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/5/679?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/5/694?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/395?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/415?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/425?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/438?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/446?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/456?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/463?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/474?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/481?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/492?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/502?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/512?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/517?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/521?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/536?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/547?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/4/553?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/3/269?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/3/270?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/3/280?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/3/293?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/3/306?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/3/315?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/3/324?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/3/333?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/3/343?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/3/348?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/content/abstract/37/3/351?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/3/359?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/3/361?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/3/363?rss=1" />
  <rdf:li rdf:resource="http://tpx.sagepub.com/cgi/reprint/37/3/372?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://tpx.sagepub.com:80/icons/banner/title.gif" />
</channel>

<image rdf:about="http://tpx.sagepub.com:80/icons/banner/title.gif">
<title>Toxicologic Pathology</title>
<url>http://tpx.sagepub.com:80/icons/banner/title.gif</url>
<link>http://tpx.sagepub.com</link>
</image>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/6/705?rss=1">
<title><![CDATA[The Role of the Toxicologic Pathologist in Risk Management]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/6/705?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Ochoa, R., Rousseaux, C.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309344434</dc:identifier>
<dc:title><![CDATA[The Role of the Toxicologic Pathologist in Risk Management]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>707</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>705</prism:startingPage>
<prism:section>Guest Editorial</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/708?rss=1">
<title><![CDATA[Emanuel Edward Klein--The Father of British Microbiology and the Case of the Animal Vivisection Controversy of 1875]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/708?rss=1</link>
<description><![CDATA[
<p>The new Appendix A of the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes, which gives guidelines for accommodation and care of animals and was approved on June 15, 2006, was the main reason the authors decided to investigate the origins of the regulations of animal experiments. Although one might assume that the regulation had its origin in the United Nations conventions, the truth is that its origins are a hundred years old. The authors present a case of the nineteenth-century vivisection controversy brought about by the publication of the <I>Handbook for the Physiological Laboratory</I> in 1873, in which John Burdon-Sanderson, Emanuel Edward Klein, Michael Foster, and Thomas Lauder Brunton described a series of vivisection experiments they performed on animals for research purposes. It was the first case of vivisection to be examined, processed, and condemned for inhuman behavior toward animals before an official body, leading to enactment of the Cruelty to Animals Act in 1876. The case reveals a specific ethos of science in the second half of the nineteenth century, which was characterized by a deep commitment of scientists to the scientific enterprise and their strong belief that science could solve social problems, combined with an overt insensitivity to the suffering of experimental animals. The central figure in the case was Emanuel Edward Klein, a disciple of the Central European medical tradition (Vienna Medical School) and a direct follower of the experimental school of Br&uuml;cke, Stricker, Magendie, and Bernard. Because of his undisguised attitudes and opinions on the use of vivisection, Klein became a paradigm of the new scientific identity, strongly influencing the stereotypic image of a scientist, and polarizing the public opinion on vivisection in England in the nineteenth century and for some considerable time afterward.</p>
]]></description>
<dc:creator><![CDATA[Atalic, B., Fatovic-Ferencic, S.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309345871</dc:identifier>
<dc:title><![CDATA[Emanuel Edward Klein--The Father of British Microbiology and the Case of the Animal Vivisection Controversy of 1875]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>713</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>708</prism:startingPage>
<prism:section>Historical Reviews</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/714?rss=1">
<title><![CDATA[A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/714?rss=1</link>
<description><![CDATA[
<p>The two-year cancer bioassay in rodents remains the primary testing strategy for in-life screening of compounds that might pose a potential cancer hazard. Yet experimental evidence shows that cancer is often secondary to a biological precursor effect, the mode of action is sometimes not relevant to humans, and key events leading to cancer in rodents from nongenotoxic agents usually occur well before tumorigenesis and at the same or lower doses than those producing tumors. The International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) hypothesized that the signals of importance for human cancer hazard identification can be detected in shorter-term studies. Using the National Toxicology Program (NTP) database, a retrospective analysis was conducted on sixteen chemicals with liver, lung, or kidney tumors in two-year rodent cancer bioassays, and for which short-term data were also available. For nongenotoxic compounds, results showed that cellular changes indicative of a tumorigenic endpoint can be identified for many, but not all, of the chemicals producing tumors in two-year studies after thirteen weeks utilizing conventional endpoints. Additional endpoints are needed to identify some signals not detected with routine evaluation. This effort defined critical questions that should be explored to improve the predictivity of human carcinogenic risk.</p>
]]></description>
<dc:creator><![CDATA[Boobis, A. R., Cohen, S. M., Doerrer, N. G., Galloway, S. M., Haley, P. J., Hard, G. C., Hess, F. G., Macdonald, J. S., Thibault, S., Wolf, D. C., Wright, J.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309343779</dc:identifier>
<dc:title><![CDATA[A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>732</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>714</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/733?rss=1">
<title><![CDATA[Carcinogenic Effects of MGP-7 and B[a]P on the Hamster Cheek Pouch]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/733?rss=1</link>
<description><![CDATA[
<p>This study was performed to examine the carcinogenic effects of benzo[a]pyrene (B[a]P) and manufactured gas plant (MGP) residues on the hamster cheek pouch (HCP). Syrian hamsters were treated topically with a suspension of 2%, 10%, or 20% B[a]P or 50% or 100% MGP-7 (a mixture of residues from 7 MGP sites) in mineral oil for eight (short-term study) and sixteen, twenty, twenty-eight, and thirty-two weeks (long-term study). The short-term study showed that B[a]P induced p53 protein accumulation, indicative of genotoxic damage, as well as increased cell proliferation, hyperplasia, and inflammation, which is usually associated with promotional activity. In contrast, the MGP-7 presented only marginal p53 accumulation and induction of BrdU incorporation. In the long-term experiments, animals treated with 2% and 10% of B[a]P continued to show p53 protein accumulation as well as hyperplasia and increased cell proliferation and inflammation. By thirty weeks, all the animals treated with B[a]P had a 100% incidence of squamous cell carcinoma (SCC). Animals treated with 50% and 100% MGP-7 showed only weak hyperplasia and a low proliferation rate and accumulation of p53 protein through thirty-two weeks. Benzo[a]pyrene was highly carcinogenic when used at adequate doses. Manufactured gas plant residue, however, was not carcinogenic in this model.</p>
]]></description>
<dc:creator><![CDATA[Brandon, J. L., Conti, C. J., Goldstein, L. S., DiGiovanni, J., Gimenez-Conti, I. B.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309344203</dc:identifier>
<dc:title><![CDATA[Carcinogenic Effects of MGP-7 and B[a]P on the Hamster Cheek Pouch]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>740</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>733</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/741?rss=1">
<title><![CDATA[Neoplastic and Non-neoplastic Changes in F-344 Rats Treated with Naveglitazar, a {gamma}-Dominant PPAR {alpha}/{gamma} Agonist]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/741?rss=1</link>
<description><![CDATA[
<p>The carcinogenic potential of naveglitazar, a -dominant peroxisome proliferator-activated receptor (PPAR) / dual agonist, was evaluated in a two-year study in F344 rats (0, 0.3, 1.0, or 3.0 mg/kg, males; 0, 0.1, 0.3, or 1.0 mg/kg, females). Increased mortality in male rats of the high-dose group was related to cardiac-associated lesions, neoplasms, and undetermined causes. Degeneration and hypertrophy of the myocardium occurred with dose-responsive increased incidence and severity. Neoplasms with increased incidence included sarcomas in male rats and urinary bladder neoplasms in female rats. Most sarcomas in male rats occurred in the adipose tissue of the subcutis and were diagnosed as fibrosarcomas, with fewer liposarcomas and other histologic types. Non-neoplastic changes in adipose tissue included expansion of adipose tissue in multiple sites, alterations in cytoplasmic vesicular pattern in brown and white fat, increases in stroma and mesenchymal cells, and fibrosis. The severity of chronic progressive nephropathy was decreased in a dose-responsive manner in males, and hyperplasia and neoplasia of the mammary gland were decreased in incidence in females. The adverse effects of cardiotoxicity and increased incidence of neoplasms occurred with dose-responsive incidence and/or severity, and a no-effect level for these effects was not achieved in this study.</p>
]]></description>
<dc:creator><![CDATA[Long, G. G., Reynolds, V. L., Dochterman, L. W., Ryan, T. E.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309343775</dc:identifier>
<dc:title><![CDATA[Neoplastic and Non-neoplastic Changes in F-344 Rats Treated with Naveglitazar, a {gamma}-Dominant PPAR {alpha}/{gamma} Agonist]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>753</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>741</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/754?rss=1">
<title><![CDATA[Longitudinal Studies of Cardiac Troponin-I Concentrations in Serum from Male Sprague Dawley Rats: Baseline Reference Ranges and Effects of Handling and Placebo Dosing on Biological Variability]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/754?rss=1</link>
<description><![CDATA[
<p>Serum cardiac troponin-I has been validated as a biomarker for cardiotoxicity in numerous animal models; however, baseline reference ranges for cTnI concentration in a healthy population of laboratory rats, as well as an investigation of biological cTnI variability in rats with respect to time, handling, and placebo dosing methods, have not been reported. In this study, we used an ultrasensitive cTnI immunoassay to quantify hourly concentrations of cTnI in live rats handled under standard laboratory conditions using 15 &micro;L of serum per determination. The baseline reference range (mean 4.94 pg/mL, range 1&ndash;15 pg/mL, 99% confidence interval [CI]) of cTnI concentration in rats was consistent with previously reported reference ranges for cTnI in humans (1&ndash;12 pg/mL) and with preliminary studies in dogs (1&ndash;4 pg/mL) and monkeys (4&ndash;5 pg/mL) using the same cTnI assay method. In addition, cTnI concentrations in individual rat serum samples show minimal biological variability over a twenty-four-hour interval when compared to a meaningful reference change value of 193% to 206%. Furthermore, measurements of cTnI concentration were consistent within the reference limits in individual rats over long periods and under three different standard laboratory handling conditions. Thus, using this new method, rats can be followed longitudinally at hourly intervals, and a doubling of cTnI concentration would be significant above biological variability. This is a new paradigm for preclinical testing, which allows transient changes in cTnI concentration to be accurately quantified. This understanding of baseline and biological variability in rats will be fundamental for designing and analyzing future studies that assess potential cardiotoxicity in drug development.</p>
]]></description>
<dc:creator><![CDATA[Schultze, A. E., Carpenter, K. H., Wians, F. H., Agee, S. J., Minyard, J., Lu, Q. A., Todd, J., Konrad, R. J.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309343777</dc:identifier>
<dc:title><![CDATA[Longitudinal Studies of Cardiac Troponin-I Concentrations in Serum from Male Sprague Dawley Rats: Baseline Reference Ranges and Effects of Handling and Placebo Dosing on Biological Variability]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>760</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>754</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/761?rss=1">
<title><![CDATA[Mechanistic Study on Hepatocarcinogenesis of Piperonyl Butoxide in Mice]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/761?rss=1</link>
<description><![CDATA[
<p>To clarify the mechanism of piperonyl butoxide (PBO)-induced hepatocarcinogenesis in mice, male mice were subjected to a two-thirds partial hepatectomy, N-diethylnitrosamine (DEN) initiation, and a diet containing 0.6% PBO for eight weeks. The incidence of -glutamyl transpeptidase (GGT)-positive foci and PCNA-positive cells was significantly increased in the DEN + PBO group compared with the DEN-alone group. Real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis showed up-regulation of genes related to metabolism, such as cytochrome P450 1A1 and 2B10, and metabolic stress, such as <I>Por, Nqo1, Nrf2, abcc3</I>, and <I>abcc4</I>. Early responsive genes downstream of mitogen-activated protein kinase (MAPK), such as <I>c-fos, c-jun, c-myc</I>, and activating transcription factor 3 (<I>ATF3</I>), were also up-regulated in this group. Positive immunohistochemical staining for ATF3 was diffusely observed in nonproliferating hepatocytes of the DEN + PBO group, but altered foci were negative or weakly positive for ATF3. The nuclei of hepatocytes within ATF3-negative foci were positive for cyclin D. Thus PBO can induce oxidative stress, activate the MAPK pathway, and increase ATF3 transcript levels in hepatocytes outside the altered foci during the early stage of PBO-induced hepatocarcinogenesis in mice.</p>
]]></description>
<dc:creator><![CDATA[Kawai, M., Saegusa, Y., Jin, M., Dewa, Y., Nishimura, J., Harada, T., Shibutani, M., Mitsumori, K.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309344087</dc:identifier>
<dc:title><![CDATA[Mechanistic Study on Hepatocarcinogenesis of Piperonyl Butoxide in Mice]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>769</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>761</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/770?rss=1">
<title><![CDATA[Administration of Miltefosine and Meglumine Antimoniate in Healthy Dogs: Clinicopathological Evaluation of the Impact on the Kidneys]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/770?rss=1</link>
<description><![CDATA[
<p>In canine leishmaniosis (CanL), kidneys are affected in virtually all dogs. Treatment of CanL is limited in Europe to meglumine antimoniate and miltefosine. This study evaluated the pharmacological, toxicological, and pathological effects of both drugs in healthy beagle dogs. Four male and four female dogs were divided into two groups. The animals in Group 1 were administered an oral solution of 2% of miltefosine at 2 mg/kg b.w. once a day, for twenty-eight days. The animals in Group 2 were administered a preparation of meglumine antimoniate at 100 mg/kg b.w. subcutaneously once a day for twenty-eight days. After treatment, all dogs were followed-up for a further twenty-eight days. Dogs were observed daily and clinically examined ten times throughout the study. On days -1 and 55 a renal biopsy was performed on all dogs and analyzed by light microscopy, immunofluorescence, and electron microscopy. All the examinations failed to demonstrate any lesions in the miltefosine-treated dogs. Conversely, all the meglumine antimoniate&ndash;treated dogs demonstrated severe tubular damage, characterized by tubular cell necrosis and apoptosis. In conclusion, although no clinical signs of renal disease were evident, the use of meglumine antimoniate in the pharmacological treatment approach of CanL-affected dogs should be carefully considered.</p>
]]></description>
<dc:creator><![CDATA[Bianciardi, P., Brovida, C., Valente, M., Aresu, L., Cavicchioli, L., Vischer, C., Giroud, L., Castagnaro, M.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309344088</dc:identifier>
<dc:title><![CDATA[Administration of Miltefosine and Meglumine Antimoniate in Healthy Dogs: Clinicopathological Evaluation of the Impact on the Kidneys]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>775</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>770</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/776?rss=1">
<title><![CDATA[Kainic Acid-induced F-344 Rat model of Mesial Temporal Lobe Epilepsy: Gene Expression and Canonical Pathways]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/776?rss=1</link>
<description><![CDATA[
<p>Mesial temporal lobe epilepsy (MTLE) is a severe neurological condition of unknown pathogenesis for which several animal models have been developed. To obtain a better understanding of the underlying molecular mechanisms and identify potential biomarkers of lesion progression, we used a rat kainic acid (KA) treatment model of MTLE coupled with global gene expression analysis to examine temporal (four hours, days 3, 14, or 28) gene regulation relative to hippocampal histopathological changes. The authors recommend reviewing the companion histopathology paper (<cross-ref type="bib" refid="b62-0370776">Sharma et al. 2008</cross-ref>) to get a better understanding of the work presented here. Analysis of filtered gene expression data using Ingenuity Pathways Analysis (Ingenuity Systems, <inter-ref locator="http://www.ingenuity.com" locator-type="url">http://www.ingenuity.com</inter-ref>) revealed that a number of genes pertaining to neuronal plasticity (RhoA, Rac1, Cdc42, BDNF, and Trk), neurodegeneration (Caspase3, Calpain 1, Bax, a Cytochrome c, and Smac/Diablo), and inflammation/immune-response pathways (TNF-, CCL2, Cox2) were modulated in a temporal fashion after KA treatment. Expression changes for selected genes known to have a role in neuronal plasticity were subsequently validated by quantitative polymerase chain reaction (qPCR). Notably, canonical pathway analysis revealed that a number of genes within the axon guidance signaling canonical pathway were up-regulated from Days 3 to 28, which correlated with aberrant mossy fiber (MF) sprouting observed histologically beginning at Day 6. Importantly, analysis of the gene expression data also identified potential biomarkers for monitoring neurodegeneration (Cox2) and neuronal/synaptic plasticity (Kalrn).</p>
]]></description>
<dc:creator><![CDATA[Sharma, A. K., Searfoss, G. H., Reams, R. Y., Jordan, W. H., Snyder, P. W., Chiang, A. Y., Jolly, R. A., Ryan, T. P.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309344202</dc:identifier>
<dc:title><![CDATA[Kainic Acid-induced F-344 Rat model of Mesial Temporal Lobe Epilepsy: Gene Expression and Canonical Pathways]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>789</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>776</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/790?rss=1">
<title><![CDATA[Effects of the Antifungal Agent Itraconazole on Proliferative Changes of the Forestomach Mucosa in Alloxan-induced Diabetic Rats]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/790?rss=1</link>
<description><![CDATA[
<p>Alloxan-induced diabetic rats frequently exhibit proliferative lesions of squamous hyperplasia accompanied by chronic inflammation and <I>Candida albicans</I> infection in the forestomach, and some lesions progress to squamous cell carcinoma (SCC). <I>Candida</I> infection causes not only hyperplastic changes with inflammation but might also lead to SCC in human oral mucosa. Thus, the present study was conducted to examine the effects of the antifungal agent itraconazole (ITCZ) on proliferative and inflammatory changes of the forestomach in alloxan-induced diabetic WBN/Kob rats. Diabetes was induced by alloxan at fifteen weeks of age. Rats were allocated to three groups at forty-five weeks of age and were given ITCZ by gavage 0 (vehicle control), 5, and 10 mg/kg/day for four weeks, and they were sacrificed at the sixty-fifth week of age. Mucosal hyperplastic changes were consistently accompanied by inflammation and <I>Candida</I> infections in the 0 mg/kg group. These lesions were reduced by ITCZ (0 mg/kg; 100%, 5 mg/kg; 53.5%, 10 mg/kg; 61.5%). Squamous cell carcinoma was detected in three rats from the 0 mg/kg, but only one rat from the 10 mg/kg dose groups in this study. Itraconazole reduced the degree of mucosal hyperplasia, inflammatory changes, and <I>Candida</I> infection. Therefore, <I>C. albicans</I> infection was an important factor in pathogenesis of mucosal proliferation and inflammation.</p>
]]></description>
<dc:creator><![CDATA[Sano, T., Ozaki, K., Kodama, Y., Matsuura, T., Narama, I.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309344204</dc:identifier>
<dc:title><![CDATA[Effects of the Antifungal Agent Itraconazole on Proliferative Changes of the Forestomach Mucosa in Alloxan-induced Diabetic Rats]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>798</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>790</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/799?rss=1">
<title><![CDATA[Systemic Inflammatory Response Syndrome in Nonhuman Primates Culminating in Multiple Organ Failure, Acute Lung Injury, and Disseminated Intravascular Coagulation]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/799?rss=1</link>
<description><![CDATA[
<p>The systemic inflammatory response syndrome (SIRS) is a clinicopathological manifestation of overexuberant acute-phase inflammation caused by infectious or noninfectious etiologies. The systemic release of pro-inflammatory cytokines, chemokines, and lipid and vasoactive mediators induces endothelial damage and microvascular thrombosis, potentially culminating in disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and multiple organ dysfunction (MOD) or failure (MOF). We present five cases in the pig-tailed macaque and olive baboon where SIRS resulted in MOF, ARDS, DIC, and the Waterhouse-Friderichsen syndrome; each with gross and histological elements manifested as edema, deposition of fibrin, hemorrhage, and thrombosis. In the described cases, SIRS was the end-common pathway for multiple risk factors that parallel those documented in humans: major surgery, obstetric complications, and infection. The diagnosis of SIRS should be considered when evaluating nonhuman primate (NHP) cases of MOF manifesting with histological evidence of vascular leakage. Experimental manipulation of NHP models may be complicated by SIRS and accompanying rapid clinical decompensation. Such adverse events may compromise toxicological studies and should be avoided when possible.</p>
]]></description>
<dc:creator><![CDATA[Hukkanen, R. R., Liggitt, H. D., Murnane, R. D., Frevert, C. W.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309343778</dc:identifier>
<dc:title><![CDATA[Systemic Inflammatory Response Syndrome in Nonhuman Primates Culminating in Multiple Organ Failure, Acute Lung Injury, and Disseminated Intravascular Coagulation]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>804</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>799</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/805?rss=1">
<title><![CDATA[Activation of Calcitonin Gene-Related Peptide Receptor during Ozone Inhalation Contributes to Airway Epithelial Injury and Repair]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/805?rss=1</link>
<description><![CDATA[
<p>The authors investigated the importance of the neuropeptide, calcitonin gene-related peptide (CGRP), in epithelial injury, repair, and neutrophil emigration after ozone exposure. Wistar rats were administered either a CGRP-receptor antagonist (CGRP<SUB>8&ndash;37</SUB>) or saline and exposed to 8 hours of 1-ppm ozone or filtered air with an 8-hour postexposure period. Immediately after exposure, ethidium homodimer was instilled into lungs as a marker of necrotic airway epithelial cells. After fixation, airway dissected lung lobes were stained for 5'-bromo-2'-deoxyuridine, a marker of epithelial proliferation. Positive epithelial cells were quantified in specific airway generations. Rats treated with CGRP<SUB>8&ndash;37</SUB> had significantly reduced epithelial injury in terminal bronchioles and reduced epithelial proliferation in proximal airways and terminal bronchioles. Bronchoalveolar lavage and sections of terminal bronchioles showed no significant difference in the number of neutrophils emigrating into airways in CGRP<SUB>8&ndash;37</SUB>-treated rats. The airway epithelial cell line, HBE-1, showed no difference in the number of oxidant stress positive cells during exposure to hydrogen peroxide and a range of CGRP<SUB>8&ndash;37</SUB> doses, demonstrating no antioxidant effect of CGRP<SUB>8&ndash;37</SUB>. We conclude that activation of CGRP receptors during ozone inhalation contributes to airway epithelial injury and subsequent epithelial proliferation, a critical component of repair, but does not influence neutrophil emigration into airways.</p>
]]></description>
<dc:creator><![CDATA[Oslund, K. L., Hyde, D. M., Putney, L. F., Alfaro, M. F., Walby, W. F., Tyler, N. K., Schelegle, E. S.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309345691</dc:identifier>
<dc:title><![CDATA[Activation of Calcitonin Gene-Related Peptide Receptor during Ozone Inhalation Contributes to Airway Epithelial Injury and Repair]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>813</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>805</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/814?rss=1">
<title><![CDATA[Spontaneous Cardiomyopathy in Cynomolgus Monkeys (Macaca Fascicularis)]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/814?rss=1</link>
<description><![CDATA[
<p>A previously undescribed spontaneous cardiomyopathy was identified by routine light microscopic examination of the heart from four clinically healthy purpose-bred cynomolgus monkeys that ranged from four to nine years of age and included 2 males and 2 females. Special stains of Sirius red, Masson&rsquo;s trichrome, and Mallory&rsquo;s phosphotungstic acid hematoxylin (PTAH); and immunohistochemistry using anti-CD68, troponin-I, and desmin antibodies were used to facilitate lesion characterization and assess cardiomyocyte viability. Microscopically, the apical to mid-ventricular myocardium to subendocardium had foci of cardiomyocyte disarray with cytoplasmic pallor to stippling and karyomegaly, vacuolization of the perimyseal connective tissue, a meshwork of fibrous tissue that concentrated around medium-sized blood vessels and dissected between or less often replaced affected cardiomyocytes; and a minimal, predominantly macrophage infiltrate. The disrupted cardiomyocytes were immunoreactive to desmin and troponin-I antibodies and had a normal cross-striation pattern by PTAH, indicating the chronic cardiomyopathy was not associated with active cardiomyocyte damage. The consistent distribution and morphology of the cardiomyopathy suggested a common etiology and pathogenesis. The features were reminiscent of chronic catecholamine-induced experimental cardiomyopathy and stress cardiomyopathy in monkeys and humans, respectively. This report documents another spontaneous heart lesion in clinically healthy monkeys for consideration during interpretation of toxicology studies.</p>
]]></description>
<dc:creator><![CDATA[Zabka, T. S., Irwin, M., Albassam, M. A.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309345692</dc:identifier>
<dc:title><![CDATA[Spontaneous Cardiomyopathy in Cynomolgus Monkeys (Macaca Fascicularis)]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>818</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>814</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/6/819?rss=1">
<title><![CDATA[Intralobar Nephroblastematosis in a Nine-week-old Wistar Rat]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/6/819?rss=1</link>
<description><![CDATA[
<p>Intralobar nephroblastematosis (ILNB) is a precursor lesion to the development of nephroblastoma (NB) in rats. Unilateral ILNB was observed in the kidney of a nine-week-old female Wistar rat (Crl:WI) from a short-term toxicity study. Clinical pathology and urinalysis did not reveal altered renal function. This microscopic, unencapsulated lesion consisted of basophilic sheets of blastemal cells that did not include a prominent mesenchymal component. These cells expanded in the interstitium, which trapped and compressed few normal renal tubules. The blastemal cells moderately differentiated to form rosettes, primitive tubules, and a glomeruloid body. Multifocally, the lumen of primitive tubules contained eosinophilic secretions with basophilic material in the center. The diagnostic criteria used were compared and differentiated with renal dysplasia, nephrogenic rest, NB in rats, and with that of the identical lesion in children.</p>
]]></description>
<dc:creator><![CDATA[Kalaiselvan, P., Mathur, K.Y., Pande, V.V., Madheswaran, R., Bhelonde, J.J., Shelar, P.D., Udupa, V., Shingatgeri, V.M.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309343776</dc:identifier>
<dc:title><![CDATA[Intralobar Nephroblastematosis in a Nine-week-old Wistar Rat]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>825</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>819</prism:startingPage>
<prism:section>Case Report</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/6/826?rss=1">
<title><![CDATA[Regulatory Forum for Toxicologic Pathology: A Two-year Update]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/6/826?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Schafer, K., Francke-Carroll, S., Hutto, D., Neef, N., Silverman, L., Vahle, J., Whitney, K.]]></dc:creator>
<dc:date>Tue, 22 Sep 2009 16:58:29 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309346747</dc:identifier>
<dc:title><![CDATA[Regulatory Forum for Toxicologic Pathology: A Two-year Update]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>826</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>826</prism:startingPage>
<prism:section>Regulatory Forum</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/5/569?rss=1">
<title><![CDATA[Introducing the "Guest Editorial"]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/5/569?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Foster, J. R.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:06 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309339040</dc:identifier>
<dc:title><![CDATA[Introducing the "Guest Editorial"]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>569</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>569</prism:startingPage>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/5/570?rss=1">
<title><![CDATA[The Re-emergence (or the Decline) of Toxicologic Pathology]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/5/570?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Alden, C. L.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:06 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309338941</dc:identifier>
<dc:title><![CDATA[The Re-emergence (or the Decline) of Toxicologic Pathology]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>571</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>570</prism:startingPage>
<prism:section>Guest Editorial</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/5/572?rss=1">
<title><![CDATA[Occult Cardiotoxicity--Toxic Effects on Cardiac Ischemic Tolerance]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/5/572?rss=1</link>
<description><![CDATA[
<p>The outcome of cardiac ischemic events depends not only on the extent and duration of the ischemic stimulus but also on the myocardial intrinsic tolerance to ischemic injury. Cardiac ischemic tolerance reflects myocardial functional reserves that are not always used when the tissue is appropriately oxygenated. Ischemic tolerance is modulated by ubiquitous signal transduction pathways, transcription factors and cellular enzymes, converging on the mitochondria as the main end effector. Therefore, drugs and toxins affecting these pathways may impair cardiac ischemic tolerance without affecting myocardial integrity or function in oxygenated conditions. Such effect would not be detected by current toxicological studies but would considerably influence the outcome of ischemic events. The authors refer to such effect as "occult cardiotoxicity." In this review, the authors summarize current knowledge about main mechanisms that determine cardiac ischemic tolerance, methods to assess it, and the effects of drugs and toxins on it. The authors offer a view that low cardiac ischemic tolerance is a premorbid status and, therefore, that occult cardiotoxicity is a significant potential source of cardiac morbidity. The authors propose that toxicologic assessment of compounds would include the assessment of their effect on cardiac ischemic tolerance.</p>
]]></description>
<dc:creator><![CDATA[Golomb, E., Nyska, A., Schwalb, H.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:06 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309339503</dc:identifier>
<dc:title><![CDATA[Occult Cardiotoxicity--Toxic Effects on Cardiac Ischemic Tolerance]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>593</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>572</prism:startingPage>
<prism:section>Invited Review</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/5/594?rss=1">
<title><![CDATA[Smoking-associated Squamous Metaplasia in Olfactory Mucosa of Patients with Chronic Rhinosinusitis]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/5/594?rss=1</link>
<description><![CDATA[
<p>Few studies have examined the induction of squamous metaplasia in human olfactory nasal tissue caused by tobacco use and the implications it may have for olfaction, particularly when there are pre-existing insults, such as chronic rhinosinusitis (CRS). Quantitative histopathological analyses were performed on Alcian blue- and H&amp;E-stained sections of nasal biopsies taken from the upper aspect of the middle turbinate of CRS patients. Chronic rhinosinusitis patients who were current smokers had a predominance of squamous metaplasia in the olfactory sensory epithelium, whereas CRS patients who were nonsmokers and were not exposed to secondhand cigarette smoke had a prevalence of goblet cell hyperplasia. In spite of this difference, the groups did not differ significantly in olfactory threshold sensitivity. The impact of primary cigarette smoke on olfaction and a possible role of squamous metaplasia in preserving olfactory neurogenesis are discussed.</p>
]]></description>
<dc:creator><![CDATA[Yee, K. K., Pribitkin, E. A., Cowart, B. J., Vainius, A. A., Klock, C. T., Rosen, D., Hahn, C.-G., Rawson, N. E.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:06 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309338055</dc:identifier>
<dc:title><![CDATA[Smoking-associated Squamous Metaplasia in Olfactory Mucosa of Patients with Chronic Rhinosinusitis]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>598</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>594</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/5/599?rss=1">
<title><![CDATA[Histological and Immunohistochemical Studies on Spontaneous Rat Astrocytomas and Malignant Reticulosis]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/5/599?rss=1</link>
<description><![CDATA[
<p>Among spontaneous neoplasms of the rat central nervous system, the discrimination between astrocytoma and malignant reticulosis (MR) is sometimes difficult because of their similar cell morphology and infiltration patterns. In the present study, we carried out histological and immunohistochemical analyses on a total of sixty-four cases in Sprague-Dawley and F344 rats. These cases were diagnosed as benign/malignant astrocytoma containing no neoplastic oligodendroglial elements or MR according to the diagnostic criteria of the World Health Organization International Classification of Rodent Tumors (<cross-ref type="bib" refid="b13-0370599">Mohr et al. 1994</cross-ref>). Astrocytomas were divided into three types and MR into two types based on the number of lesions, cellularity and infiltration patterns, and so on. Although the neoplastic cells from all types showed various immunoreactivities for RM-4 (anti-rat macrophages and dendritic cells), ED-1, and/or vimentin, there were no distinctive differences among these types, and most cells that were positive for RM-4 were also positive for ED-1. None of the tumor types showed any reactivity for GFAP or S-100 protein. From the results of morphological and immunohistochemical examinations, it was indicated that there are no distinctive differences between spontaneous astrocytomas and MR in rats, and they are probably derived from the same cell lineage, that is, microglia, macrophage, or radial glia.</p>
]]></description>
<dc:creator><![CDATA[Nagatani, M., Ando, R., Yamakawa, S., Saito, T., Tamura, K.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:06 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309338385</dc:identifier>
<dc:title><![CDATA[Histological and Immunohistochemical Studies on Spontaneous Rat Astrocytomas and Malignant Reticulosis]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>605</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>599</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/5/606?rss=1">
<title><![CDATA[Safety and Biodistribution Profile of Placental-derived Mesenchymal Stromal Cells (PLX-PAD) Following Intramuscular Delivery]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/5/606?rss=1</link>
<description><![CDATA[
<p>The administration of mesenchymal stromal cells (MSCs) provides an exciting emerging therapeutic modality for the treatment of peripheral arterial disease, a condition that is associated with critical limb ischemia as its end stage. Placental-derived MSCs, termed PLX-PAD cells, are stable adhesive stromal cells isolated from full-term human placentae, cultured on carriers, and expanded in a bioreactor called the PluriX. These cells can be expanded in vitro without phenotypic or karyotypic changes. We studied the safety and biodistribution properties of PLX-PAD cells following intramuscular administration in NOD/SCID mice. No significant clinical signs, hematological and biochemical parameters, or major pathological changes were found in PLX-PAD-treated animals in comparison to vehicle controls. Several animals in the control and PLX-PAD-treated groups developed thymic malignant lymphoma, first seen after one month, as expected in this mouse strain. In addition, both groups developed spontaneous mesenteric vessel inflammation. Real-time quantitative polymerase chain reaction (RT-qPCR) demonstrated that distribution of PLX-PAD cells was confined to the injection site. Placental-derived MSCs remained in this site with gradual decrease in concentration during a three-month period. In view of these data, we conclude that the administration of PLX-PAD cells is not associated with any adverse effects in NOD/SCID mice.</p>
]]></description>
<dc:creator><![CDATA[Ramot, Y., Meiron, M., Toren, A., Steiner, M., Nyska, A.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:06 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309338383</dc:identifier>
<dc:title><![CDATA[Safety and Biodistribution Profile of Placental-derived Mesenchymal Stromal Cells (PLX-PAD) Following Intramuscular Delivery]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>616</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>606</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/5/617?rss=1">
<title><![CDATA[Qualification of Cardiac Troponin I Concentration in Mouse Serum Using Isoproterenol and Implementation in Pharmacology Studies to Accelerate Drug Development]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/5/617?rss=1</link>
<description><![CDATA[
<p>Cardiac troponin I is a useful biomarker of myocardial injury, but its use in mice and application to early drug discovery are not well described. The authors investigated the relationship between cTnI concentration in serum and histologic lesions in heart tissue from mice treated with isoproterenol (ISO). Cardiac TnI concentrations in serum increased in a dose-dependant manner and remained increased twenty-four to forty-eight hours after a single administration of isoproterenol. Increased cTnI concentration was of greater magnitude and longer duration than increased fatty acid binding protein 3 concentration, aspartate aminotransferase activity, and creatine kinase activity in serum. Isoproterenol-induced increases in cTnI concentrations were both greater and more sustained in BALB/c than in CD1 mice and correlated with incidence and severity of lesions observed in heart sections from both strains. In drug development studies in BALB/c mice with novel kinase inhibitors, cTnI concentration was a reliable stand-alone biomarker of cardiac injury and was used in combination with measurements of <I>in vivo</I> target inhibition to demonstrate an off-target contribution to cardiotoxicity. Additional attributes, including low cost and rapid turnaround time, made cTnI concentration in serum invaluable for detecting cardiotoxicity, exploring structure&ndash;activity relationships, and prioritizing development of compounds with improved safety profiles early in drug discovery.</p>
]]></description>
<dc:creator><![CDATA[Engle, S. K., Jordan, W. H., Pritt, M. L., Chiang, A. Y., Davis, M. A., Zimmermann, J. L., Rudmann, D. G., Heinz-Taheny, K. M., Irizarry, A. R., Yamamoto, Y., Mendel, D., Schultze, A. E., Cornwell, P. D., Watson, D. E.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:06 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309339502</dc:identifier>
<dc:title><![CDATA[Qualification of Cardiac Troponin I Concentration in Mouse Serum Using Isoproterenol and Implementation in Pharmacology Studies to Accelerate Drug Development]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>628</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>617</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/5/629?rss=1">
<title><![CDATA[Differences in Immunolocalization of Kim-1, RPA-1, and RPA-2 in Kidneys of Gentamicin-, Cisplatin-, and Valproic Acid-Treated Rats: Potential Role of iNOS and Nitrotyrosine]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/5/629?rss=1</link>
<description><![CDATA[
<p>The present study compared the immunolocalization of Kim-1, renal papillary antigen (RPA)-1, and RPA-2 with that of inducible nitric oxide synthase (iNOS) and nitrotyrosine in kidneys of gentamicin sulfate (Gen)- and cisplatin (Cis)-treated rats. The specificity of acute kidney injury (AKI) biomarkers, iNOS, and nitrotyrosine was evaluated by dosing rats with valproic acid (VPA). Sprague-Dawley (SD) rats were injected subcutaneously (sc) with 100 mg/kg/day of Gen for six or fourteen days; a single intraperitoneal (ip) dose of 1, 3, or 6 mg/kg of Cis; or 650 mg/kg/day of VPA (ip) for four days. In Gen-treated rats, Kim-1 was expressed in the epithelial cells, mainly in the S1/S2 segments but less so in the S3 segment, and RPA-1 was increased in the epithelial cells of collecting ducts (CD) in the cortex. Spatial expression of iNOS or nitrotyrosine with Kim-1 or RPA-1 was detected. In Cis-treated rats, Kim-1 was expressed only in the S3 segment cells, and RPA-1 and RPA-2 were increased in the epithelial cells of medullary CD or medullary loop of Henle (LH), respectively. Spatial expression of iNOS or nitrotyrosine with RPA-1 or RPA-2 was also identified. These findings suggest that peroxynitrite formation may be involved in the pathogenesis of Gen and Cis nephrotoxicity and that Kim-1, RPA-1, and RPA-2 have the potential to serve as site-specific biomarkers for Gen or Cis AKI.</p>
]]></description>
<dc:creator><![CDATA[Zhang, J., Goering, P. L., Espandiari, P., Shaw, M., Bonventre, J. V., Vaidya, V. S., Brown, R. P., Keenan, J., Kilty, C. G., Sadrieh, N., Hanig, J. P.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:06 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309339605</dc:identifier>
<dc:title><![CDATA[Differences in Immunolocalization of Kim-1, RPA-1, and RPA-2 in Kidneys of Gentamicin-, Cisplatin-, and Valproic Acid-Treated Rats: Potential Role of iNOS and Nitrotyrosine]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>643</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>629</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/5/644?rss=1">
<title><![CDATA[Effects of a Cyclooxygenase-2 Preferential Inhibitor in Young Healthy Dogs Exposed to Air Pollution: A Pilot Study]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/5/644?rss=1</link>
<description><![CDATA[
<p>Residency in cities with high air pollution is associated with neuroinflammation and neurodegeneration in healthy children, young adults, and dogs. Nonsteroidal anti-inflammatory drugs may offer neuroprotection. The authors measured the plasma concentrations of 3-nitrotyrosine and the cerebro-spinal-fluid concentrations of prostaglandin E2 metabolite and the oligomeric form of amyloid derived diffusible ligand; measured the mRNA expression of cyclooxygenase-2, interleukin 1&beta;, CD14, and Aquaporin-4 in target brain areas; and evaluated brain MRI, cognition, and neuropathology in 8 dogs treated with a preferential cyclooxygenase-2 inhibitor (Nimesulide<sup>&reg;</sup>) versus 7 untreated litter-matched Mexico City dogs. Nimesulide<sup>&reg;</sup> significantly decreased nitrotyrosine in plasma (<I>p</I> &lt; .0001), frontal gray IL1&beta; (<I>p</I> = .03), and heart IL1&beta; (<I>p</I> = .02). No effect was seen in mRNA COX2, amyloid, and PGE2 in CSF or the MRI white matter lesions. All exposed dogs exhibited olfactory bulb and frontal accumulation of A&beta;<SUB>42</SUB> in neurons and blood vessels and frontal vascular subcortical pathology. White matter hyperintense MRI frontal lesions were seen in 4/6 non-treated and 6/8 treated dogs. Nonsteroidal anti-inflammatory drugs may offer limited neuroprotection in the setting of severe air pollution exposures. The search for potentially beneficial drugs useful to ameliorate the brain effects of pollution represents an enormous clinical challenge.</p>
]]></description>
<dc:creator><![CDATA[Calderon-Garciduenas, L., Mora-Tiscareno, A., Gomez-Garza, G., Carrasco-Portugal, M. D. C., Perez-Guille, B., Flores-Murrieta, F. J., Perez-Guille, G., Osnaya, N., Juarez-Olguin, H., Monroy, M. E., Monroy, S., Gonzalez-Maciel, A., Reynoso-Robles, R., Villarreal-Calderon, R., Patel, S. A., Kumarathasan, P., Vincent, R., Henriquez-Roldan, C., Torres-Jardon, R., Maronpot, R. R.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:06 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309340277</dc:identifier>
<dc:title><![CDATA[Effects of a Cyclooxygenase-2 Preferential Inhibitor in Young Healthy Dogs Exposed to Air Pollution: A Pilot Study]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>660</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>644</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/5/661?rss=1">
<title><![CDATA[Histopathological Features of Capillaria hepatica Infection in Laboratory Rabbits]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/5/661?rss=1</link>
<description><![CDATA[
<p><I>Capillaria hepatica</I> is a nematode parasite of wild rodents and other mammals. Adult worms inhabit the liver. Recently, during the necropsy examination of a group of 160 rabbits from a commercial supplier, firm pale or cystic areas (1&ndash;5 mm) were noted on the liver in thirteen animals. On further investigation, these animals were found to be infected with <I>C. hepatica</I>. The histopathological features of the infection in the rabbit are described for the first time and diagnostic features recorded. Lesions were identified predominantly in portal tracts consisting of dilated bile ducts with luminal debris, peribiliary inflammatory cell infiltrates, and fibrosis. Large granulomas (macrogranulomas) were evident in portal areas and involved the bile ducts. Macrogranulomas contained collections of characteristic <I>C. hepatica</I> eggs, macrophages, eosinophils, and lymphocytes. Small granulomas (microgranulomas), characterized by epithelioid macrophages surrounded by lymphocytes and eosinophils, were also identified. <I>C. hepatica</I> eggs were also observed in the lumina of the bile ducts and gall bladder. No adult <I>C. hepatica</I> worms were identified. Oocysts of <I>Eimeria stiedae</I> were also evident in the biliary epithelium in some animals. The unique characteristics of the <I>C. hepatica</I> life cycle are described, and the differential diagnosis of hepatic capillariasis is discussed.</p>
]]></description>
<dc:creator><![CDATA[Mowat, V., Turton, J., Stewart, J., Lui, K. C., Pilling, A. M.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:06 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309339501</dc:identifier>
<dc:title><![CDATA[Histopathological Features of Capillaria hepatica Infection in Laboratory Rabbits]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>666</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>661</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/5/667?rss=1">
<title><![CDATA[Spontaneous Aortitis in the Balb/c Mouse]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/5/667?rss=1</link>
<description><![CDATA[
<p>We examined whether high incidence rates (18%&ndash;56%) of inflammation in the root of the aorta detected in a Balb/c mouse model for hind limb ischemia were related to the surgical procedure. Twenty mice underwent ligation of the femoral artery; incidences of aortic root inflammation were compared to those observed in controls. We used a multiple-section sampling method to increase the sensitivity of the diagnostic rates. Although a cumulative incidence of 12.5% was found, no difference was seen in the overall incidence rates between the control and the surgically treated groups. Evaluation of blood levels of inflammatory cytokines showed that ligation of the femoral artery produced higher levels of interleukin-6 in the surgically transected group of mice. The development of spontaneous arteritis in this strain must be considered in future studies.</p>
]]></description>
<dc:creator><![CDATA[Ramot, Y., Manno, R. A., Okazaki, Y., Krakovsky, M., Lamensdorf, I., Meiron, M., Toren, A., Zehavi-Goldstein, E., Vezzali, E., Nyska, A.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:07 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309338384</dc:identifier>
<dc:title><![CDATA[Spontaneous Aortitis in the Balb/c Mouse]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>671</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>667</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/5/672?rss=1">
<title><![CDATA[Points to Consider on the Statistical Analysis of Rodent Cancer Bioassay Data When Incorporating Historical Control Data]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/5/672?rss=1</link>
<description><![CDATA[
<p>Researchers routinely use historical control data (HCD) when analyzing rodent carcinogenicity data obtained in a particular study. Although the concurrent control group is considered to be the most relevant group to compare with the dose groups, the HCD provides a broader perspective to assist in understanding the significance of the current study. The HCD is used to provide information about the incidences of spontaneous tumors and malignant systemic disorders such as lymphoma and leukemia. This article presents some possible ways of incorporating the HCD when analyzing data from a rodent cancer bioassay. Specifically, exploratory (informal) and formal statistical procedures for analyzing such data are reviewed. The boxplot is presented as an exploratory tool that describes the current data in the context of the distribution of the HCD. It will also identify potential outliers that would not be otherwise be flagged using standard methods such as the mean, standard deviation, and range. The various options for the statistical analysis of HCD presented here do not necessarily represent standard practice.</p>
]]></description>
<dc:creator><![CDATA[Elmore, S. A., Peddada, S. D.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:07 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309339606</dc:identifier>
<dc:title><![CDATA[Points to Consider on the Statistical Analysis of Rodent Cancer Bioassay Data When Incorporating Historical Control Data]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>676</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>672</prism:startingPage>
<prism:section>Statistics</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/5/677?rss=1">
<title><![CDATA[Potential for a Global Historical Control Database for Proliferative Rodent Lesions]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/5/677?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Keenan, C., Elmore, S., Francke-Carroll, S., Kerlin, R., Peddada, S., Pletcher, J., Rinke, M., Schmidt, S. P., Taylor, I., Wolf, D. C.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:07 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309336155</dc:identifier>
<dc:title><![CDATA[Potential for a Global Historical Control Database for Proliferative Rodent Lesions]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>678</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>677</prism:startingPage>
<prism:section>Regulatory Forum</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/5/679?rss=1">
<title><![CDATA[Best Practices for Use of Historical Control Data of Proliferative Rodent Lesions]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/5/679?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Keenan, C., Elmore, S., Francke-Carroll, S., Kemp, R., Kerlin, R., Peddada, S., Pletcher, J., Rinke, M., Schmidt, S. P., Taylor, I., Wolf, D. C.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:07 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309336154</dc:identifier>
<dc:title><![CDATA[Best Practices for Use of Historical Control Data of Proliferative Rodent Lesions]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>693</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>679</prism:startingPage>
<prism:section>Regulatory Forum</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/5/694?rss=1">
<title><![CDATA[The International Nomenclature Project: An Update]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/5/694?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Vahle, J., Bradley, A., Harada, T., Herbert, R., Kaufmann, W., Kellner, R., Mann, P., Pyrah, I., Rittinghausen, S., Tanaka, T.]]></dc:creator>
<dc:date>Tue, 28 Jul 2009 08:38:07 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309340278</dc:identifier>
<dc:title><![CDATA[The International Nomenclature Project: An Update]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>697</prism:endingPage>
<prism:publicationDate>2009-08-01</prism:publicationDate>
<prism:startingPage>694</prism:startingPage>
<prism:section>Inhand Global Editorial and Steering Committee</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/395?rss=1">
<title><![CDATA[Histology Atlas of the Developing Mouse Heart with Emphasis on E11.5 to E18.5]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/395?rss=1</link>
<description><![CDATA[
<p>In humans, congenital heart diseases are common. Since the rapid progression of transgenic technologies, the mouse has become the major animal model of defective cardiovascular development. Moreover, genetically modified mice frequently die in utero, commonly due to abnormal cardiovascular development. A variety of publications address specific developmental stages or structures of the mouse heart, but a single reference reviewing and describing the anatomy and histology of cardiac developmental events, stage by stage, has not been available. The aim of this color atlas, which demonstrates embryonic/fetal heart development, is to provide a tool for pathologists and biomedical scientists to use for detailed histological evaluation of hematoxylin and eosin (H&amp;E)-stained sections of the developing mouse heart with emphasis on embryonic days (E) 11.5&ndash;18.5. The selected images illustrate the main structures and developmental events at each stage and serve as reference material for the confirmation of the chronological age of the embryo/early fetus and assist in the identification of any abnormalities. An extensive review of the literature covering cardiac development pre-E11.5 is summarized in the introduction. Although the focus of this atlas is on the descriptive anatomic and histological development of the normal mouse heart from E11.5 to E18.5, potential embryonic cardiac lesions are discussed with a list of the most common transgenic pre- and perinatal heart defects. Representative images of hearts at E11.5&ndash;15.5 and E18.5 are provided in Figures 2&ndash;4, 6, 8, and 9. A complete set of labeled images (Figures E11.5&ndash;18.5) is available on the CD enclosed in this issue of Toxicologic Pathology. All digital images can be viewed online at https://niehsimages.epl-inc.com with the username "ToxPath" and the password "embryohearts."</p>
]]></description>
<dc:creator><![CDATA[Savolainen, S. M., Foley, J. F., Elmore, S. A.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309335060</dc:identifier>
<dc:title><![CDATA[Histology Atlas of the Developing Mouse Heart with Emphasis on E11.5 to E18.5]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>414</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>395</prism:startingPage>
<prism:section>Invited Review</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/415?rss=1">
<title><![CDATA[Thyroid Histopathology Assessments for the Amphibian Metamorphosis Assay to Detect Thyroid-active Substances]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/415?rss=1</link>
<description><![CDATA[
<p>In support of an Organization for Economic Cooperation and Development (OECD) Amphibian Metamorphosis Assay (AMA) Test Guideline for the detection of substances that interact with the hypothalamic-pituitary-thyroid axis, a document was developed that provides a standardized approach for evaluating the histology/histopathology of thyroid glands in metamorphosing <I>Xenopus laevis</I> tadpoles. Here, a consolidated description of histology evaluation practices, core diagnostic criteria and severity grading schemes for the AMA, an atlas of the normal architecture of amphibian thyroid glands over the course of metamorphosis, and the core diagnostic criteria with examples of severity grades is provided. Core diagnostic criteria include thyroid gland hypertrophy/atrophy, follicular cell hypertrophy, and follicular cell hyperplasia. The severity grading scheme is semiquantitative and employs a four-grade approach describing ranges of variation within assigned ordinal classes: not remarkable, mild, moderate, and severe. The purpose of this severity grading approach is to provide an efficient, semi-objective tool for comparing changes (compound-related effects) among animals, treatment groups, and studies. Proposed descriptions of lesions for scoring the four core criteria are also given.</p>
]]></description>
<dc:creator><![CDATA[Grim, K. C., Wolfe, M., Braunbeck, T., Iguchi, T., Ohta, Y., Tooi, O., Touart, L., Wolf, D. C., Tietge, J.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309335063</dc:identifier>
<dc:title><![CDATA[Thyroid Histopathology Assessments for the Amphibian Metamorphosis Assay to Detect Thyroid-active Substances]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>424</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>415</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/425?rss=1">
<title><![CDATA[Dimethylarsinic Acid in Drinking Water Changed the Morphology of Urinary Bladder but Not the Expression of DNA Repair Genes of Bladder Transitional Epithelium in F344 Rats]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/425?rss=1</link>
<description><![CDATA[
<p>Inorganic arsenic increases urinary bladder transitional cell carcinoma in humans. In F344 rats, dimethylarsinic acid (DMA[V]) increases transitional cell carcinoma. Arsenic-induced inhibition of DNA repair has been reported in cultured cell lines and in lymphocytes of arsenic-exposed humans, but it has not been studied in urinary bladder. Should inhibition of DNA damage repair in transitional epithelium occur, it may contribute to carcinogenesis or cocarcinogenesis. We investigated morphology and expression of DNA repair genes in F344 rat transitional cells following up to 100 ppm DMA(V) in drinking water for four weeks. Mitochondria were very sensitive to DMA(V), and swollen mitochondria appeared to be the main source of vacuoles in the transitional epithelium. Real-time reverse transcriptase polymerase chain reaction (Real-Time RT PCR) showed the mRNA levels of tested DNA repair genes, ataxia telangectasia mutant (ATM), X-ray repair cross-complementing group 1 (XRCC1), excision repair cross-complementing group 3/xeroderma pigmentosum B (ERCC3/XPB), and DNA polymerase &beta; (Pol&beta;), were not altered by DMA(V). These data suggested that either DMA(V) does not affect DNA repair in the bladder or DMA(V) affects DNA repair without affecting baseline mRNA levels of repair genes. The possibility remains that DMA(V) may lower damage-induced increases in repair gene expression or cause post-translational modification of repair enzymes.</p>
]]></description>
<dc:creator><![CDATA[Wang, A., Wolf, D. C., Sen, B., Knapp, G. W., Holladay, S. D., Huckle, W. R., Caceci, T., Robertson, J. L.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309334147</dc:identifier>
<dc:title><![CDATA[Dimethylarsinic Acid in Drinking Water Changed the Morphology of Urinary Bladder but Not the Expression of DNA Repair Genes of Bladder Transitional Epithelium in F344 Rats]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>437</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>425</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/438?rss=1">
<title><![CDATA[FYX-051, a Xanthine Oxidoreductase Inhibitor, Induces Nephropathy in Rats, but not in Monkeys]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/438?rss=1</link>
<description><![CDATA[
<p>The present studies were performed to investigate the possible mechanism of marked species differences on nephropathy found in the long-term toxicity study of FYX-051, a xanthine oxidoreductase inhibitor. In the twenty-six-week dose toxicity study in the rat, in which FYX-051 was administered by oral gavage at 0.04, 0.2, and 1 mg/kg, xanthine-mediated nephropathy was seen only at 1 mg/kg, despite the presence of xanthine crystals in urine at 0.2 mg/kg and more; however, in the fifty-two-week dose toxicity study in the monkey, in which FYX-051 was administered by oral gavage at 30, 100, and 300 mg/kg, no toxicities were seen, even at 300 mg/kg. These outcomes showed there would be 1500-fold or more differences in the mode of intrarenal xanthine deposition between rats and monkeys. Thus we performed the mechanistic study, and the following outcomes were obtained. First, the amount of urinary purine metabolites was thirty-fold higher in rats than in monkeys. Second, urinary xanthine solubility was sixfold higher in monkeys than in rats. Third, exposure levels of FYX-051 were five-fold higher in rats than in monkeys. Therefore, the present study indicated that the combined effects of purine metabolism, urinary xanthine solubility, and toxicokinetics would contribute to species differences in nephropathy, that is, absence of xanthine-mediated nephropathy in monkeys even at the highest dose of FYX-051.</p>
]]></description>
<dc:creator><![CDATA[Shimo, T., Ashizawa, N., Moto, M., Matsumoto, K., Iwanaga, T., Nagata, O.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332995</dc:identifier>
<dc:title><![CDATA[FYX-051, a Xanthine Oxidoreductase Inhibitor, Induces Nephropathy in Rats, but not in Monkeys]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>445</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>438</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/446?rss=1">
<title><![CDATA[Molecular Expression Analysis of {beta}-Naphthoflavone-induced Hepatocellular Tumors in Rats]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/446?rss=1</link>
<description><![CDATA[
<p>The present study was performed to characterize molecular expression levels of preneoplastic and neoplastic lesions induced by &beta;-naphthoflavone (BNF), an aryl hydrocarbon receptor (AhR) agonist in rat hepatocarcinogenesis. Male F344 rats were initiated with an intraperitoneal injection of 200 mg/kg <I>N</I>-diethylnitrosamine, and two weeks later, they were fed a diet containing 0% or 1% BNF for twenty-eight weeks. All animals were subjected to a two-thirds partial hepatectomy at week 3 and sacrificed at week 30. Histopathologically, BNF increased the incidence and multiplicity of altered foci (1.7-fold and 3.3-fold) and hepatocellular adenomas (HCAs) (4.0-fold and 4.7-fold). Immunohistochemically, BNF increased the number of proliferating cell nuclear antigen (PCNA)-positive cells in altered foci (2.3-fold) and HCAs (6.7-fold) compared with the surrounding tissue and decreased the staining of cell cycle regulators (P21, C/EBP). In addition, loss of reactivity for AhR-regulated (CYP1A1, CYP1B1) molecules and increased reactivity of Nrf-2-regulated (AKR7, GPX2) molecules were also observed in proliferative lesions. Furthermore, increased staining of histone deacetylase (HDAC1) in the nucleus was prominent in HCAs. The differential expression patterns were confirmed at mRNA levels by real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis. These results suggest that enhanced cell proliferation and protection against oxidative stress play an important role in BNF-induced hepatocarcinogenesis in rats.</p>
]]></description>
<dc:creator><![CDATA[Dewa, Y., Nishimura, J., Jin, M., Kawai, M., Saegusa, Y., Harada, T., Shibutani, M., Mitsumori, K.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309335062</dc:identifier>
<dc:title><![CDATA[Molecular Expression Analysis of {beta}-Naphthoflavone-induced Hepatocellular Tumors in Rats]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>455</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>446</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/456?rss=1">
<title><![CDATA[Translocation Pathway of the Intratracheally Instilled C60 Fullerene from the Lung into the Blood Circulation in the Mouse: Possible Association of Diffusion and Caveolae-mediated Pinocytosis]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/456?rss=1</link>
<description><![CDATA[
<p>Ultrafine particles are ubiquitous in ambient urban and indoor air from multiple sources and may contribute to adverse respiratory and cardiovascular diseases. Recently, it has been demonstrated that ultrafine particles (UFPs) are translocated from the lung into the systemic circulation. The exact pathway, however, for the translocation in the lung remains unclear. In this study, we examined the translocation pathway of intratracheally instilled C60 fullerene particles from the lung into the blood circulation in the mouse. Using light microscopy, aggregated particles of fullerene were observed in the capillary lumen in the lung and the pulmonary lymph nodes immediately after instillation. Electron microscopic analysis demonstrated an increased number of pinocytotic vesicles (caveolae) of various sizes in the type 1 alveolar epithelial cells (AEC) and endothelial cells; occasional caveolae containing some particulate substances were observed. In addition, particles of various sizes were observed throughout the structure of the air-blood barrier (ABB). These findings suggest that fullerene particles may pass the ABB by both diffusion and caveolae-mediated pinocytosis, resulting in immediate translocation into the systemic circulation.</p>
]]></description>
<dc:creator><![CDATA[Naota, M., Shimada, A., Morita, T., Inoue, K., Takano, H.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309335059</dc:identifier>
<dc:title><![CDATA[Translocation Pathway of the Intratracheally Instilled C60 Fullerene from the Lung into the Blood Circulation in the Mouse: Possible Association of Diffusion and Caveolae-mediated Pinocytosis]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>462</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>456</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/463?rss=1">
<title><![CDATA[Participation of Functionally Different Macrophage Populations and Monocyte Chemoattractant Protein-1 in Early Stages of Thioacetamide-induced Rat Hepatic Injury]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/463?rss=1</link>
<description><![CDATA[
<p>Macrophages are crucial in hepatic fibrogenesis. In acute hepatic necrosis induced in rats by a single injection of 300 mg/kg body weight (BW) of thioacetamide (TAA), macrophage properties were investigated using single or double immunohistochemistry. Macrophages reacting with anti-CD68, anti-CD163, or major histocompatibility complex (anti-MHC) class II antibody appeared in injured centrilobular areas on days 1-5 after injection. Increased expression of CD68 and CD163 reflect phagocytosis and production of pro-inflammatory factors, respectively. There were also macrophages double-positive to CD68/CD163, CD68/MHC class II, or CD163/MHC class II; of these, macrophages double-positive to CD68/MHC class II were most frequent, indicating that macrophages with enhanced phagocytic activity came to express MHC class II. The appearance of these macrophages corresponded to increased expression of mRNAs of monocyte chemoattractant protein-1 (MCP-1), a chemokine, on day 1, and TGF-&beta;1, a fibrogenic factor, on day 3. Some hepatic stellate cells (HSCs) in injured areas reacted with anti-MCP-1 antibody. To investigate the effects of MCP-1, we added MCP-1 to HS-P, a rat macrophage line. Addition of MCP-1 increased immunoexpression for CD68 and CD163 and up-regulated TGF-&beta;1 mRNA expression. Collectively, macrophages in acute hepatic necrosis may express different properties such as phagocytosis, MHC class II expression, and TGF-&beta;1 production; such expression may be influenced by MCP-1 produced by HSCs.</p>
]]></description>
<dc:creator><![CDATA[Mori, Y., Izawa, T., Takenaka, S., Kuwamura, M., Yamate, J.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309335634</dc:identifier>
<dc:title><![CDATA[Participation of Functionally Different Macrophage Populations and Monocyte Chemoattractant Protein-1 in Early Stages of Thioacetamide-induced Rat Hepatic Injury]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>473</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>463</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/474?rss=1">
<title><![CDATA[The Metrial Gland in the Rat and Its Similarities to Granular Cell Tumors]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/474?rss=1</link>
<description><![CDATA[
<p>Metrial glands are normal structures located in the mesometrial triangle of the pregnant rat uterus from gestational day (GD) 8 through termination of pregnancy. Metrial glands are composed of a dynamic mixed cell population of granulated metrial gland (GMG) cells, endometrial stromal cells, trophoblasts, blood vessels, and fibroblasts. Collections of similar cells may be seen in association with pseudopregnancy and other hormonal disturbances. Granulated metrial gland cells are the hallmark cell of the metrial gland. They are bone-marrow-derived, perforin-positive, natural killer cells that proliferate in the pregnant uterus. Understanding the normal histogenesis of the metrial gland and recognizing the possible existence of GMG cells and a reactive metrial gland in the nonpregnant state are important when examining any uterine lesion that contains granulated cells. This report demonstrates that the cellular composition, morphology, and immunohistochemical staining profile of normal metrial glands are similar to reported granular cell neoplasms in rats and mice. The possibility of a non-neoplastic lesion involving the metrial gland should be considered when proliferative lesions involving granulated cells are observed in the uterus of mice and rats from nonclinical toxicity studies. Positive immunohistochemical staining for perforin and S100 would assist in the classification of such lesions as a reactive metrial gland or decidual reaction.</p>
]]></description>
<dc:creator><![CDATA[Picut, C. A., Swanson, C. L., Parker, R. F., Scully, K. L., Parker, G. A.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309335632</dc:identifier>
<dc:title><![CDATA[The Metrial Gland in the Rat and Its Similarities to Granular Cell Tumors]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>480</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>474</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/481?rss=1">
<title><![CDATA[{gamma}-Tocopherol Attenuates Ozone-induced Exacerbation of Allergic Rhinosinusitis in Rats]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/481?rss=1</link>
<description><![CDATA[
<p>Compared to healthy subjects, individuals with allergic airway disease (e.g., asthma, allergic rhinitis) have enhanced inflammatory responses to inhaled ozone. We created a rodent model of ozone-enhanced allergic nasal responses in Brown Norway rats to test the therapeutic effects of the dietary supplement -tocopherol (T). Ovalbumin (OVA)-sensitized rats were intranasally challenged with 0% or 0.5% OVA (in saline) on Days 1 and 2, and then exposed to 0 or 1 ppm ozone (eight hours/day) on Days 4 and 5. Rats were also given 0 or 100 mg/kg T (p.o., in corn oil) on days 2 through 5, beginning twelve hours after the last OVA challenge. On Day 6, nasal tissues were collected for histological evaluation and morphometric analyses of intraepithelial mucosubstances (IM) and eosinophilic inflammation. Nasal septal tissue was microdissected and analyzed by reverse transcriptase polymerase chain reaction (RT-PCR) for mucin glycoprotein 5AC (MUC5AC) expression levels. Histological analysis revealed mild to moderate eosinophil influx in the mucosa lining the nasal airways and maxillary sinus of OVA-challenged rats (eosinophilic rhinosinusitis). Ozone exposure of allergic rats further increased eosinophils in the maxillary sinus (400%), nasolacrimal duct (250%), and proximal midseptum (150%). Storage of intraepithelial mucosubstances (IM) was not significantly affected by OVA challenge in filtered air-exposed rats, but it was increased by ozone in the septum (45%) and maxillary sinus (55%) of allergic compared to control rats. Treatment with T attenuated the ozone/ OVA-induced synergistic increases in IM and mucosal eosinophils in both nasal and paranasal airways. -Tocopherol also blocked OVA and ozone-induced MUC5AC gene expression. Together, these data describe a unique model of ozone enhancement of allergic rhinosinusitis and the novel therapeutic efficacy of a common supplement, T, to inhibit ozone exacerbation of allergic airway responses.</p>
]]></description>
<dc:creator><![CDATA[Wagner, J. G., Harkema, J. R., Jiang, Q., Illek, B., Ames, B. N., Peden, D. B.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309335630</dc:identifier>
<dc:title><![CDATA[{gamma}-Tocopherol Attenuates Ozone-induced Exacerbation of Allergic Rhinosinusitis in Rats]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>491</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>481</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/492?rss=1">
<title><![CDATA[The Influence of Estrogen on Hepatobiliary Osteopontin (SPP1) Expression in a Female Rodent Model of Alcoholic Steatohepatitis]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/492?rss=1</link>
<description><![CDATA[
<p>Our recent studies suggest that higher neutrophil infiltration in females correlates with increased hepatobiliary expression of osteopontin (OPN) in alcoholic steatohepatitis (ASH). The objective of this study was to understand the role of alcohol in altering estrogen levels in females by examining the effect of ethanol (EtOH) on the estrous cycle and then investigate the potential relationship between estradiol (E2) and hepatobiliary OPN expression in a female rat ASH model. Ovariectomized (OVX) and E2-implanted OVX rats in the ASH group were evaluated for OPN mRNA and protein expression. Low doses of E2 resulted in significant down-regulation of OPN protein and mRNA as compared to the OVX group. However, with increasing doses of E2, there was up-regulation of both OPN mRNA and protein. Osteopontin was localized primarily to the biliary epithelium. Liver injury assessed by serum ALT and histopathology revealed a pattern similar to OPN expression. In all groups, hepatic neutrophilic infiltration correlated positively with OPN expression. Based on these data, we conclude that in our ASH model, low doses of E2 appear to be hepatoprotective, whereas the protective effect appears to diminish with increasing doses of E2, although additional cause and effect studies are needed for confirmation.</p>
]]></description>
<dc:creator><![CDATA[Banerjee, A., Rose, R., Johnson, G. A., Burghardt, R. C., Ramaiah, S. K.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309335633</dc:identifier>
<dc:title><![CDATA[The Influence of Estrogen on Hepatobiliary Osteopontin (SPP1) Expression in a Female Rodent Model of Alcoholic Steatohepatitis]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>501</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>492</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/502?rss=1">
<title><![CDATA[Gene Expression Studies Reveal That DNA Damage, Vascular Perturbation, and Inflammation Contribute to the Pathogenesis of Carbonyl Sulfide Neurotoxicity]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/502?rss=1</link>
<description><![CDATA[
<p>Carbonyl sulfide (COS) is an odorless gas that produces highly reproducible lesions in the central nervous system. In the present study, the time course for the development of the neurotoxicological lesions was defined and the gene expression changes occurring in the posterior colliculus upon exposure to COS were characterized. Fischer 344 rats were exposed to 0 or 500 ppm COS for one, two, three, four, five, eight, or ten days, six hours per day. On days 1 and 2, no morphological changes were detected; on day 3, 10/10 (100%) rats had necrosis in the posterior colliculi; and on day 4 and later, necrosis was observed in numerous areas of the brain. Important gene expression changes occurring in the posterior colliculi after one or two days of COS exposure that were predictive of the subsequent morphological findings included up-regulation of genes associated with DNA damage and G1/S checkpoint regulation (KLF4, BTG2, GADD45g), apoptosis (TGM2, GADD45g, RIPK3), and vascular mediators (ADAMTS, CTGF, CYR61, VEGFC). Proinflammatory mediators (CCL2, CEBPD) were up-regulated prior to increases in expression of the astrocytic marker GFAP and macrophage marker CSF2rb1. These gene expression findings were predictive of later CNS lesions caused by COS exposure and serve as a model for future investigations into the mechanisms of disease in the central nervous system.</p>
]]></description>
<dc:creator><![CDATA[Morrison, J. P., Ton, T.-V., Collins, J. B., Switzer, R. C., Little, P. B., Morgan, D. L., Sills, R. C.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309335631</dc:identifier>
<dc:title><![CDATA[Gene Expression Studies Reveal That DNA Damage, Vascular Perturbation, and Inflammation Contribute to the Pathogenesis of Carbonyl Sulfide Neurotoxicity]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>511</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>502</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/512?rss=1">
<title><![CDATA[Histological Biocompatibility of a Stainless Steel Miniature Glaucoma Drainage Device in Humans: A Case Report]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/512?rss=1</link>
<description><![CDATA[
<p>The purpose of this study was to evaluate the histological biocompatibility of a stainless steel miniature glaucoma drainage device. Twenty-four months before death due to heart failure, this seventy-three-year-old female patient underwent filtration surgery for primary open-angle glaucoma uncontrolled in the right eye. The device was implanted at the limbus under a scleral flap. For histopathological evaluation, two corneoscleral specimens were embedded in methacrylate blocks sectioned to a thickness of 50 microns, polished and stained with periodic acid schiff. Some sections included a longitudinal cross-section of the implant. At the interface between the spur and the flange of the device and the cornea, there was a small shoulder of fibrous tissue. A thin, fibrous capsule covered the remainder of the body of the device up to the distal tip. No inflammatory cells occurred within the fibrous capsule. No material or blockage was noted within the lumen. Our results support the biological inertness of the device.</p>
]]></description>
<dc:creator><![CDATA[De Feo, F., Jacobson, S., Nyska, A., Pagani, P., Traverso, C. E.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309336150</dc:identifier>
<dc:title><![CDATA[Histological Biocompatibility of a Stainless Steel Miniature Glaucoma Drainage Device in Humans: A Case Report]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>516</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>512</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/517?rss=1">
<title><![CDATA[Fenofibrate-Induced Muscular Toxicity Is Associated with a Metabolic Shift Limited to Type-1 Muscles in Rats]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/517?rss=1</link>
<description><![CDATA[
<p>Morphological changes and mRNA expression levels in type-1 predominant soleus and type-2 predominant tensor fasciae latae muscles of rats treated with fenofibrate were investigated. After fenofibrate by oral gavage at 300 mg/kg/day for 28 days, degeneration/necrosis and regeneration of muscle fibers, cellular infiltration, and fibrosis were seen in soleus muscle. Additionally, expression of PDK4, CPT1-M, CPT2, and FACO mRNAs was increased. In contrast, no morphological changes or mRNA induction were apparent in tensor fasciae latae muscle. These data suggest that sensitivity to fenofibrate-induced muscle toxicity differs among muscles, with only type-1 fibers being susceptible. The up-regulation of PDK4, CPTs and FACO mRNA expression in soleus muscle indicates that the energy source is switched from glucose to fatty acids, and this might be related to the observed fenofibrate-induced muscular toxicity.</p>
]]></description>
<dc:creator><![CDATA[Okada, M., Sano, F., Ikeda, I., Sugimoto, J., Takagi, S., Sakai, H., Yanai, T.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309336151</dc:identifier>
<dc:title><![CDATA[Fenofibrate-Induced Muscular Toxicity Is Associated with a Metabolic Shift Limited to Type-1 Muscles in Rats]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>520</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>517</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/521?rss=1">
<title><![CDATA[Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/521?rss=1</link>
<description><![CDATA[
<p>Peroxisome proliferator-activated receptor- (PPAR) agonists such as fenofibrate are used to treat dyslipidemia. Although fenofibrate is considered safe in humans, it is known to cause hepatocarcinogenesis in rodents. To evaluate untargeted metabolic profiling as a tool for gaining insight into the underlying pharmacology and hepatotoxicology, Fischer 344 male rats were dosed with 300 mg/kg/day of fenofibrate for 14 days and the urine and plasma were analyzed on days 2 and 14. A combination of liquid and gas chromatography mass spectrometry returned the profiles of 486 plasma and 932 urinary metabolites. Aside from known pharmacological effects, such as accelerated fatty acid &beta;-oxidation and reduced plasma cholesterol, new observations on the drug&rsquo;s impact on cellular metabolism were generated. Reductions in TCA cycle intermediates and biochemical evidence of lactic acidosis demonstrated that energy metabolism homeostasis was altered. Perturbation of the glutathione biosynthesis and elevation of oxidative stress markers were observed. Furthermore, tryptophan metabolism was up-regulated, resulting in accumulation of tryptophan metabolites associated with reactive oxygen species generation, suggesting the possibility of oxidative stress as a mechanism of nongenotoxic carcinogenesis. Finally, several metabolites related to liver function, kidney function, cell damage, and cell proliferation were altered by fenofibrate-induced toxicity at this dose.</p>
]]></description>
<dc:creator><![CDATA[Ohta, T., Masutomi, N., Tsutsui, N., Sakairi, T., Mitchell, M., Milburn, M. V., Ryals, J. A., Beebe, K. D., Guo, L.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309336152</dc:identifier>
<dc:title><![CDATA[Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>535</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>521</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/536?rss=1">
<title><![CDATA[Neutralization of IL-10 Exacerbates Cycloheximide-Induced Hepatocellular Apoptosis and Necrosis]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/536?rss=1</link>
<description><![CDATA[
<p>Cycloheximide (CHX)-induced liver injury in rats has been characterized by hepatocellular apoptosis and necrosis. We previously reported that Kupffer cell inactivation causes a reduction of IL-10 production, resulting in the exacerbation of CHX-induced liver injury. In this study, we directly evaluate the role of IL-10 in liver injury by a pretreatment with anti-IL-10 neutralizing antibody (IL-10Ab). Rats were given goat IgG or IL-10Ab before being treated with CHX (CHX group or IL-10Ab/CHX group). In the CHX group, the CHX treatment markedly induced hepatic mRNA and serum protein levels of IL-10. The up-regulation of IL-10 was significantly suppressed in the IL-10Ab/CHX group. Blocking IL-10 in the IL-10Ab/ CHX group led to greater increases in hepatic mRNA and serum levels of proinflammatory cytokines, such as TNF- and IL-6. The IL-10Ab/CHX group developed more severe hepatocellular apoptosis, neutrophil transmigration, and necrotic change of hepatocytes compared with the CHX group. The caspase activities and mRNA levels of Cc120, LOX-1, and E-selectin in the livers were significantly higher in the IL-10Ab/CHX group than the CHX group. These results demonstrate that IL-10 plays an important role in counteracting the effect of proinflammatory cytokines, such as a TNF signaling cascade, and in attenuating the CHX-induced liver injury.</p>
]]></description>
<dc:creator><![CDATA[Kumagai, K., Ito, K., Ando, Y., Hakamata, S., Teranishi, M., Nakayama, H., Manabe, S.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:43 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309336153</dc:identifier>
<dc:title><![CDATA[Neutralization of IL-10 Exacerbates Cycloheximide-Induced Hepatocellular Apoptosis and Necrosis]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>546</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>536</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/547?rss=1">
<title><![CDATA[Spontaneous Hibernomas in Sprague-Dawley Rats]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/547?rss=1</link>
<description><![CDATA[
<p>Hibernomas are rare neoplasms originating in brown adipose tissue of humans and other animal species, including laboratory animals. Background incidence values for these tumors in all common strains of laboratory rats are generally accepted as being &lt;0.1%. Between April 2000 and April 2007, however, sixty-two hibernomas (an overall prevalence of 3.52%) were observed in a total of 1760 Sprague-Dawley rats assigned to three carcinogenesis bioassays at two separate research laboratories. All rats were obtained from Charles River&rsquo;s breeding facilities in either Portage, Michigan, or Raleigh, North Carolina. Tumors (twenty-nine benign and thirty-three malignant) were randomly distributed among test article&ndash;treated and control groups and were considered to be spontaneous. Most tumors originated in the thoracic cavity, and they were usually described as soft, mottled to tan masses with nodular to lobulated profiles. Immunohistochemical procedures for uncoupling protein 1 (UCP1) confirmed brown adipose tissue as the site of origin rather than white fat. The marked increase in hibernomas in our studies suggests that greater numbers of spontaneous hibernomas may be sporadically encountered in future carcinogenesis studies with Sprague-Dawley rats. The increased potential for hibernomas to arise as spontaneous neoplasms has important implications in studies involving peroxisome proliferators&ndash;activated receptor (PPAR) drugs, lipophilic environmental chemicals (e.g., polychlorinated biphenyls), and other molecules or physiologic processes (e.g., &beta;-adrenergic stimulation) that may target brown fat adipocytes.</p>
]]></description>
<dc:creator><![CDATA[Bruner, R. H., Novilla, M. N., Picut, C. A., Kirkpatrick, J. B., O'Neill, T. P., Scully, K. L., Lawrence, W. B., Goodman, D. G., Saladino, B. H., Peters, D. G., Parker, G. A.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:44 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309335061</dc:identifier>
<dc:title><![CDATA[Spontaneous Hibernomas in Sprague-Dawley Rats]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>552</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>547</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/4/553?rss=1">
<title><![CDATA[Global Recognition of Qualified Toxicologic Pathologists: Credential Review as a Potential Route for Recognizing the Proficiency of Pathologists Involved in Regulatory-type Nonclinical Studies]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/4/553?rss=1</link>
<description><![CDATA[
<p>Recent international summits of the International Federation of Societies of Toxicologic Pathologists have debated the desirability and potential means by which the proficiency of an individual toxicologic pathologist might be recognized and communicated throughout the world. The present article describes the advantages and disadvantages of implementing such a global recognition system by any means and provides a proposal whereby recognition might be accorded via rigorous credential review of a practitioner&rsquo;s education and experience.</p>
]]></description>
<dc:creator><![CDATA[Ettlin, R. A., Bolon, B., Pyrah, I., Konishi, Y., Black, H. E.]]></dc:creator>
<dc:date>Wed, 20 May 2009 16:14:44 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309336156</dc:identifier>
<dc:title><![CDATA[Global Recognition of Qualified Toxicologic Pathologists: Credential Review as a Potential Route for Recognizing the Proficiency of Pathologists Involved in Regulatory-type Nonclinical Studies]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>561</prism:endingPage>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:startingPage>553</prism:startingPage>
<prism:section>Current Opinion</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/3/269?rss=1">
<title><![CDATA[Regulatory Forum]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/3/269?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Foster, J. R.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:45 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332610</dc:identifier>
<dc:title><![CDATA[Regulatory Forum]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>269</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>269</prism:startingPage>
<prism:section>Editorial</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/3/270?rss=1">
<title><![CDATA[Nephrotic Syndrome Induced by Dibasic Sodium Phosphate Injections for Twenty-eight Days in Rats]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/3/270?rss=1</link>
<description><![CDATA[
<p>Sprague-Dawley rats received once daily tail-vein injections of 360 mM dibasic sodium phosphate solution at 8 mL/kg for fourteen or twenty-eight days. Clinical examination revealed persistent proteinuria from three days after the first dosing and thereafter severe proteinuria from eight days or later in the phosphate-treated groups. Proteinuria developed without remission even after fourteen-day withdrawal in the fourteen-day dosed group. Phosphate-treated animals developed lipemia, hypercholesterolemia, anemia, higher serum fibrinogen levels, and lower serum albumin/globulin ratios on day 29. Renal weight increased significantly compared with control animals, and the kidneys appeared pale and enlarged with a rough surface. Histopathologically, glomerular changes consisted of mineralization in whole glomeruli, glomerular capillary dilatation, partial adhesion of glomerular tufts to Bowman&rsquo;s capsule, and mesangiolysis. Ultrastructural lesions such as an increased number of microvilli, effacement of foot processes, and thickening of the glomerular basement membrane, and immunocytochemical changes in podocytes, mainly decreased podoplanin-positive cells and increased desmin expression, were also conspicuous in the phosphate-treated rats for twenty-eight days. Marked tubulointerstitial lesions were tubular regeneration and dilatation, protein casts, mineralization in the basement membrane, focal interstitial inflammation, and fibrosis in the cortex. These clinical and morphological changes were similar to features of human nephrotic syndrome.</p>
]]></description>
<dc:creator><![CDATA[Tsuchiya, N., Torii, M., Narama, I., Matsui, T.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332996</dc:identifier>
<dc:title><![CDATA[Nephrotic Syndrome Induced by Dibasic Sodium Phosphate Injections for Twenty-eight Days in Rats]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>279</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>270</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/3/280?rss=1">
<title><![CDATA[Discovery of Metabolomics Biomarkers for Early Detection of Nephrotoxicity]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/3/280?rss=1</link>
<description><![CDATA[
<p>Drug-induced nephrotoxicity is a major concern, since many pharmacological compounds are filtered through the kidneys for excretion into urine. To discover biochemical biomarkers useful for early identification of nephrotoxicity, metabolomic experiments were performed on Sprague-Dawley Crl:CD (SD) rats treated with the nephrotoxins gentamicin, cisplatin, or tobramycin. Using a combination of gas chromatography/mass spectrometry (GC/MS) and liquid chromatography/mass spectrometry (LC/MS), a global, nontargeted metabolomics analysis was performed on urine and kidney samples collected after one, five, and twenty-eight dosing days. Increases in polyamines and amino acids were observed in urine from drug-treated rats after a single dose, and prior to observable histological kidney damage and conventional clinical chemistry indications of nephrotoxicity. Thus, these metabolites are potential biomarkers for the early detection of drug-induced nephrotoxicity. Upon prolonged dosing, nephrotoxin-induced changes included a progressive loss of amino acids in urine, concomitant with a decrease in amino acids and nucleosides in kidney tissue. A nephrotoxicity prediction model, based on the levels of branched-chain amino acids in urine, distinguished nephrotoxin-treated samples from vehicle-control samples, with 100%, 93%, and 70% accuracy at day 28, day 5, and day 1, respectively. Thus, this panel of biomarkers may provide a noninvasive method to detect kidney injury long before the onset of histopathological kidney damage.</p>
]]></description>
<dc:creator><![CDATA[Boudonck, K. J., Mitchell, M. W., Nemet, L., Keresztes, L., Nyska, A., Shinar, D., Rosenstock, M.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332992</dc:identifier>
<dc:title><![CDATA[Discovery of Metabolomics Biomarkers for Early Detection of Nephrotoxicity]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>292</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>280</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/3/293?rss=1">
<title><![CDATA[Strain-related Differences in Urine Composition of Male Rats of Potential Relevance to Urolithiasis]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/3/293?rss=1</link>
<description><![CDATA[
<p>In carcinogenicity studies with PPAR  and / agonists, urinary bladder tumors have been reported in Harlan Sprague-Dawley (HSD) and Charles River Sprague-Dawley (SD) but not Wistar (WI) rats, with urolithiasis purported to be the inciting event. In two 3-month studies, the authors investigated strain-related differences in urine composition by sampling urine multiple times daily. Urine pH, electrolytes, creatinine, protein, citrate and oxalate levels, and serum citrate were assessed; urine sediment was analyzed by scanning electron microscopy and energy dispersive x-ray spectroscopy. HSD rats had significantly higher urine calcium than SD or WI rats, primarily as calcium phosphate-containing precipitate. When compared to SD rats, HSD rats had lower urine volume, higher urine protein, and a comparable (week 4) to lower (week 13) burden of MgNH<SUB>4</SUB>PO<SUB>4</SUB> aggregates. Relative to WI rats, HSD rats had higher urine protein and magnesium and lower serum and urine citrate. Overall, the susceptibility to urolithiasis in male rats was HSD &gt; SD &gt; WI; this was likely due to strain-related differences in the amount of urine protein (a nidus for crystal formation), lithogenic ions, citrate (an inhibitor of lithogenesis), and/or volume. Strain-related differences in urine composition need to be considered when interpreting the outcome of studies with compounds that alter urine composition.</p>
]]></description>
<dc:creator><![CDATA[Tannehill-Gregg, S. H., Dominick, M. A., Reisinger, A. J., Moehlenkamp, J. D., Waites, C. R., Stock, D. A., Sanderson, T. P., Cohen, S. M., Arnold, L. L., Schilling, B. E.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332990</dc:identifier>
<dc:title><![CDATA[Strain-related Differences in Urine Composition of Male Rats of Potential Relevance to Urolithiasis]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>305</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>293</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/3/306?rss=1">
<title><![CDATA[Effects of Chronic Exposure to Air Pollution from Sao Paulo City on Coronary of Swiss Mice, from Birth to Adulthood]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/3/306?rss=1</link>
<description><![CDATA[
<p>To explore the hypothesis that air pollution promotes cardiovascular changes, Swiss mice were continuously exposed, since birth, in two open-top chambers (filtered and nonfiltered for airborne particles &le; 0.3 &micro;m) placed 20 m from a street with heavy traffic in downtown Sao Paulo, twenty-four hours per day for four months. Fine particle (PM<SUB>2.5</SUB>) concentration was determined gravimetrically; hearts were analyzed by morphometry. There was a reduction of the PM<SUB>2.5</SUB> inside the filtered chamber (filtered = 8.61&plusmn;0.79 &micro;g/m<sup>3</sup>, nonfiltered = 18.05&plusmn;1.25 &micro;g/m<sup>3</sup>, <I>p</I> &lt; .001). Coronary arteries showed no evidence of luminal narrowing in the exposed group but presented higher collagen content in the adventitia of LV large-sized and RV midsized vessels (<I>p</I> = .001) and elastic fibers in both tunicae adventitia and intima-media of almost all sized arterioles from both ventricles (<I>p</I> = .03 and <I>p</I> = .001, respectively). We concluded that chronic exposure to urban air since birth induces mild but significant vascular structural alterations in normal individuals, presented as coronary arteriolar fibrosis and elastosis. These results might contribute to altered vascular response and ischemic events in the adulthood.</p>
]]></description>
<dc:creator><![CDATA[Akinaga, L. M. Y., Lichtenfels, A. J., Carvalho-Oliveira, R., Caldini, E. G., Dolhnikoff, M., Silva, L. F. F., De Siqueira Bueno, H. M., Pereira, L. A. A., Saldiva, P. H. N., Garcia, M. L. B.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332994</dc:identifier>
<dc:title><![CDATA[Effects of Chronic Exposure to Air Pollution from Sao Paulo City on Coronary of Swiss Mice, from Birth to Adulthood]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>314</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>306</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/3/315?rss=1">
<title><![CDATA[Eosinophilic Inclusions in Rat Clara Cells and the Effect of an Inhaled Corticosteroid]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/3/315?rss=1</link>
<description><![CDATA[
<p>Large eosinophilic cytoplasmic inclusions (ECIs) are occasionally seen in untreated rat Clara cells. Following inhalation exposure to a corticosteroid, the number of ECIs was increased. This is the first histopathological description of rat ECIs and attempted characterization by immunohistochemistry, in situ hybridization, and electron microscopy. ECIs were strongly positive for surfactant protein D (SP-D) and weakly positive for Clara cell specific protein (CCSP). Clara cell cytoplasm was positive for CCSP mRNA regardless of ECIs, but not within ECIs. Corticosteroid treatment and ECI presence did not affect the immunohistochemistry and in situ hybridization staining intensities. Electron microscopy revealed large intracytoplasmic granules with an irregular limiting membrane. The ECI number was microscopically quantified in rats from three-, six-, and twenty-four-month studies. The mean ECI counts in treated rats increased from three- to fifty-four-fold with a positive dose-related trend, when compared with vehicle controls. Although the mechanism is unclear, SP-D and to a lesser extent CCSP accumulate in the ECIs. As human bronchial epithelium does not appear to contain structures analogous to the ECI, it is suggested that the observation of an increased number of ECIs in the treated rats is not likely to be relevant for human clinical risk assessment.</p>
]]></description>
<dc:creator><![CDATA[Kambara, T., McKevitt, T. P., Francis, I., Woodfine, J. A., McCawley, S. J., Jones, S. A., Pilling, A. M., Lewis, D. J., Williams, T. C.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332989</dc:identifier>
<dc:title><![CDATA[Eosinophilic Inclusions in Rat Clara Cells and the Effect of an Inhaled Corticosteroid]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>323</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>315</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/3/324?rss=1">
<title><![CDATA[Effects of Chronic Exposure to Crack Cocaine on the Respiratory Tract of Mice]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/3/324?rss=1</link>
<description><![CDATA[
<p>Smoked cocaine (crack cocaine) causes several forms of injury to the respiratory tract, including asthma exacerbations, lung edema and hemorrhage, and nasal mucosal alterations. Few studies, however, have assessed respiratory tract pathology in habitual users of crack cocaine. Here, we describe the histological alterations in the respiratory tract of mice caused by chronic inhalation of crack cocaine. Twenty 2-month-old BALB/c mice were exposed to the smoke of 5 g crack cocaine in an inhalation chamber once a day for two months and compared to controls (n = 10). We then morphometrically analyzed nose and bronchiolar epithelial alterations, bronchiolar and alveolar macrophage cell density, alveolar hemosiderin content, and in addition determined the vasoconstriction index and the wall thickness of pulmonary arteries. The serum cocaine level was 212.5 ng/mL after a single inhalation. The mucus content of the nasal epithelium increased in crack-exposed animals, and the nasal and bronchial epithelium thickness decreased significantly. The alveolar hemosiderin content and the alveolar and bronchiolar macrophage cell density increased in animals exposed to crack. The vasoconstriction index increased in the pulmonary arteries of the exposed group. Chronic crack cocaine inhalation causes extensive histological changes along the entire respiratory tract.</p>
]]></description>
<dc:creator><![CDATA[Herculiani, P. P., Pires-Neto, R. C., Bueno, H. M. S., Zorzetto, J. C., Silva, L. C., Santos, A. B. G., Garcia, R. C. T., Yonamine, M., Detregiachi, C. R. P., Saldiva, P. H. N., Mauad, T.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623308330790</dc:identifier>
<dc:title><![CDATA[Effects of Chronic Exposure to Crack Cocaine on the Respiratory Tract of Mice]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>332</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>324</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/3/333?rss=1">
<title><![CDATA[Aflatoxin B1 and/or Hepatitis B Virus Induced Tumor Spectrum in a Genetically Engineered Hepatitis B Virus Expression and Trp53 Haploinsufficient Mouse Model System for Hepatocarcinogenesis]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/3/333?rss=1</link>
<description><![CDATA[
<p>The authors investigated the spectrum of tumors and Trp53 mutations in genetically engineered models using the FVB/N mouse that expressed the hepatitis B virus genome and/or carried a Trp53 null and wildtype allele and/or were exposed to aflatoxin B1. Liver tumor incidence was increased when all three risk factors were present. Without aflatoxin B1 exposure, neither Trp53 haploinsufficiency nor HBV expression affected liver tumor development. Liver tumor prevalence increased with aflatoxin B1 exposure (<I>p</I> &lt; .001), as thirteen of fourteen mice with liver tumors were initiated with aflatoxin B1. Liver tumors were more frequent in males (12/190) than females (2/170). Seventy-three mice developed sarcomas. Trp53 haploinsufficiency was associated with increased sarcoma incidence in males and females (<I>p</I> &lt; .001). In Trp53 haploinsufficient mice, the HBV transgene increased the risk of sarcoma in males and females (<I>p</I> &lt; .001). Lymphoma was significantly increased in Trp53 haploinsufficient FVB/N mice. There was no loss of heterozygosity at the wildtype Trp53 locus in twenty-five sarcomas or four hepatocellular tumors examined. No mutations were identified in the mRNA (exons 2&ndash;11) of Trp53 in six liver neoplasms or twenty-four sarcomas. In this model system, HBV expression affected only hepatocellular neoplasia in association with both aflatoxin B1 initiation and p53 haploinsufficiency.</p>
]]></description>
<dc:creator><![CDATA[Cullen, J. M., Brown, D. L., Kissling, G. E., Foley, J. F., Rizzo, J., Marion, P. L., Parron, V. I., French, J. E.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309333137</dc:identifier>
<dc:title><![CDATA[Aflatoxin B1 and/or Hepatitis B Virus Induced Tumor Spectrum in a Genetically Engineered Hepatitis B Virus Expression and Trp53 Haploinsufficient Mouse Model System for Hepatocarcinogenesis]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>342</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>333</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/3/343?rss=1">
<title><![CDATA[Spontaneous Ganglioneuroma Possibly Originating from the Trigeminal Ganglion in a B6C3F1 Mouse]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/3/343?rss=1</link>
<description><![CDATA[
<p>In a carcinogenicity study, a neuronal tumor in the cranial cavity was observed in a 110-week-old female B6C3F1 mouse. At necropsy, the tumor was seen at the site of the pituitary gland. Histologically, the tumor consisted of well-differentiated ganglion cells, nerve fiber/neuropil-like elements and ganglion-like cells. The tumor was composed mainly of ganglion-like cells, which were arranged in solid sheets interspersed with thin fibrovascular stroma. Nissl substance was detected at the margin in the cytoplasm of well-differentiated ganglion cells, and nerve fibers were identified by the Kluever-Barrera method. Immunohistochemically, the well-differentiated ganglion cells were positive for S-100, neurofilament protein (NF), neuron-specific enolase (NSE), synaptophysin, and chromogranin A. The nerve fiber/neuropil-like elements were positive for S-100, NF, NSE, and glial fibrillary acidic protein (GFAP), and the ganglion-like cells were strongly positive only for NSE and synaptophysin. On the other hand, there were no pituitary cells, such as prolactin-positive or adrenocorticotropic hormone (ACTH)-positive cells in the tumor tissue. Detailed histopathological examination suggested that the tumor might be a ganglioneuroma arising from the trigeminal ganglion. This report provides additional histopathological evidence of peripheral nerve neoplasms in mice.</p>
]]></description>
<dc:creator><![CDATA[Yasui, Y., Ohta, Y., Ueda, Y., Hasegawa, K., Kihara, T., Hosoi, M., Miyajima, R., Shiga, A., Imai, K., Toyoda, K.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309333786</dc:identifier>
<dc:title><![CDATA[Spontaneous Ganglioneuroma Possibly Originating from the Trigeminal Ganglion in a B6C3F1 Mouse]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>347</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>343</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/3/348?rss=1">
<title><![CDATA[Canine Cardiac Rhabdomyoma]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/3/348?rss=1</link>
<description><![CDATA[
<p>A well-circumscribed, expansile, and nonencapsulated cardiac rhabdomyoma composed of tightly arranged, large, variably sized, ovoid to irregular, swollen myocytes with deeply eosinophilic cytoplasm and varying degrees of cytoplasmic vacuolation was detected in an eight- to nine-month-old female beagle dog in a routine toxicology study. By histochemistry, the neoplasm was periodic acid-Schiff positive. By immunohistochemistry (IHC), neoplastic cells were positive for desmin and myoglobin and negative for vimentin and smooth muscle actin. Spontaneous lesions in the heart of young beagle dogs are rare in drug safety studies. On the basis of histopathology, histochemistry, and IHC findings, a diagnosis of cardiac rhabdomyoma was made. Cardiac rhabdomyoma is one of the most frequently occuring primary tumors of the heart and, by far, the most common neoplasm in human infants and children. To our knowledge, this is the first report of the canine cardiac rhabdomyoma.</p>
]]></description>
<dc:creator><![CDATA[Radi, Z. A., Metz, A.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332991</dc:identifier>
<dc:title><![CDATA[Canine Cardiac Rhabdomyoma]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>350</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>348</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/content/abstract/37/3/351?rss=1">
<title><![CDATA[Apparent Alveolar Bronchiolar Tumors Arising in the Mediastinum of F344 Rats]]></title>
<link>http://tpx.sagepub.com/cgi/content/abstract/37/3/351?rss=1</link>
<description><![CDATA[
<p>Rare tumors were observed in chronic studies in F-344 rats that were purely or largely free in the mediastinal cavity, yet had the histological architecture of alveolar bronchiolar tumors. They had originally been diagnosed as either pulmonary alveolar bronchiolar tumors, mediastinal mesotheliomas, or thymomas. The authors described these tumors, estimated the fraction of thoracic tumors that they represented, and carried out a preliminary immunohistochemical investigation of whether they were of pulmonary or mesothelial origin. Sections of 715 thoracic tumors originally diagnosed as alveolar bronchiolar tumors, mesotheliomas, or thymomas from control or treated F-344 rats in NTP two-year studies were reviewed. Thirty (4%) were found to be purely or largely mediastinal, yet to have an alveolar bronchiolar histological pattern. A subset of these tumors and some typical intrapulmonary alveolar bronchiolar carcinomas and pleural mesotheliomas were immunostained for Clara cell secretory protein (CCSP), &beta;-tubulin IV, and Wilm&rsquo;s tumor 1 susceptibility gene products (WT1). The tumors with the histological architecture of alveolar bronchiolar tumors immunostained positive for CCSP and negative for WT1, implying they might have been of alveolar bronchiolar origin, despite their predominantly mediastinal location, although more certain identification would require the use of a larger panel of antibodies.</p>
]]></description>
<dc:creator><![CDATA[Howroyd, P., Allison, N., Foley, J. F., Hardisty, J.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332988</dc:identifier>
<dc:title><![CDATA[Apparent Alveolar Bronchiolar Tumors Arising in the Mediastinum of F344 Rats]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>358</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>351</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/3/359?rss=1">
<title><![CDATA[The ACVP/STP Coalition Responds to the Continued Shortage of Veterinary Pathologists]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/3/359?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Cockerell, G., Meuten, D., Ochoa, R.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309333295</dc:identifier>
<dc:title><![CDATA[The ACVP/STP Coalition Responds to the Continued Shortage of Veterinary Pathologists]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>360</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>359</prism:startingPage>
<prism:section>Guest Editorial</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/3/361?rss=1">
<title><![CDATA[Regulatory Affairs Introduction]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/3/361?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Green, J. D.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332987</dc:identifier>
<dc:title><![CDATA[Regulatory Affairs Introduction]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>362</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>361</prism:startingPage>
<prism:section>Regulatory Affairs</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/3/363?rss=1">
<title><![CDATA[The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/3/363?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Milton, M. N., Horvath, C. J.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332997</dc:identifier>
<dc:title><![CDATA[The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>371</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>363</prism:startingPage>
<prism:section>Regulatory Affairs</prism:section>
</item>

<item rdf:about="http://tpx.sagepub.com/cgi/reprint/37/3/372?rss=1">
<title><![CDATA[The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?]]></title>
<link>http://tpx.sagepub.com/cgi/reprint/37/3/372?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Horvath, C. J., Milton, M. N.]]></dc:creator>
<dc:date>Mon, 20 Apr 2009 14:27:46 PDT</dc:date>
<dc:identifier>info:doi/10.1177/0192623309332986</dc:identifier>
<dc:title><![CDATA[The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?]]></dc:title>
<dc:publisher>Society of Toxicologic Pathology</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>37</prism:volume>
<prism:endingPage>383</prism:endingPage>
<prism:publicationDate>2009-04-01</prism:publicationDate>
<prism:startingPage>372</prism:startingPage>
<prism:section>Regulatory Affairs</prism:section>
</item>

</rdf:RDF>